love is a god as soma

phentermine diet pill message board

S. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. To ensure the use of Multaq in the appropriate patient population, sanofi-aventis U. Atrial fibrillation is a potentially life-threatening condition, with significant burden on patients, health care providers and payers. Multaq should not be given to patients who are or may become pregnant (Category X) or nursing. love is a god as soma The FDA approval is based on five international, multi-center, randomized clinical trials involving nearly 6,300 patients. love is a god as soma The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. Treatment with Multaq can be initiated in an outpatient setting. how cialis works after ejaculation

" The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure).5 million people in the European Union. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. The efficacy and safety of Multaq 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq. love is a god as soma Multaq should not be given to patients who are or may become pregnant (Category X) or nursing. love is a god as soma "We are pleased that the FDA has granted approval of Multaq for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis. what does xanax do to you

S." The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure). In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III. Multaq should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval. Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality. love is a god as soma S. love is a god as soma Such patients should not be given dronedarone. Multaq should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval.